Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
SCL Stepan Co
GRWG GrowGeneration Corp
ROG Rogers Corp
ALB Albemarle Corp
DD Dupont De Nemours Inc
SMG Scotts Miracle-Gro Co
MTX Minerals Technologies Inc
HUN Huntsman Corp
PPG PPG Industries Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$176.40
Day's Change
-0.41 (-0.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
179.14
Day's Low
173.41
Volume
(Light)
Volume:
1,221,141

10-day average volume:
3,746,478
1,221,141

Europe may give COVID vaccines full marketing authorization to avoid annual review, and WHO backs Gilead's Veklury for severe disease

10:22 am ET September 16, 2022 (MarketWatch)
Print

By Ciara Linnane

Novavax vaccine allowed for children in Israel and adolescents in Taiwan

A flurry of regulatory announcements relating to COVID treatments, vaccines and boosters dominated headlines on the pandemic Friday, with Europe now considering giving vaccines full marketing authorization to avoid having to review them every year.

The Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency (EMA) is making that recommendation for Pfizer (PFE) and BioNTech's (MRNA) mRNA vaccine called Comirnaty, according to a statement from the companies.

"The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision," said the statement.

Separately, the CHMP recommended approval of Comirnaty as a booster dose for children aged 5 through 11, to be administered at least six months after completion of a primary series of shots.

AstraZeneca PLC (AZN.LN) said the CHMP is recommending its Evusheld drug for use in COVID patients aged 12 and older who don't need supplemental oxygen but who are at risk of developing severe disease. The European Medicines Agency's recommendation is based on the Tackle Phase 3 treatment data, which proved that Evusheld reduced risk of severe Covid-19 or death, as Dow Jones Newswires reported

The World Health Organization on Thursday expanded its recommended guide for Gilead's (GILD) COVID-19 treatment Veklury.

The WHO updated its guidelines to recommend the drug to treat patients with severe COVID, an expansion from simply "those with non-severe COVID-19 at the highest risk of hospitalization." In late July, European Commission regulators recommended that Veklury be used as an expanded COVID-19 treatment.

On Friday, the CHMP recommended extending Veklury, also called remdesivir, for use in pediatric patients The European Commission will review the recommendation, and if adopted, Veklury could become the only authorized treatment for adolescents at high risk of developing severe disease and children with COVID who require supplemental oxygen.

Novavax (NVAX) said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditional technology than the mRNA used in the vaccines developed by Pfizer and Moderna.

Separately, the company said it had has also won emergency use authorization in Taiwan for adolescents aged 12 through 17.

The news comes as U.S. known cases of COVID are continuing to ease, although the true tally is likely higher given how many people are testing at home, where the data are not being collected. The daily average for new cases stood at 64,308 on Thursday, according to a New York Times tracker, down 28% from two weeks ago.

The daily average for hospitalizations was down 11% at 33,143 while the daily average for deaths is down 4% to 491.

From the CDC: Stay Up to Date with COVID-19 Vaccines Including Boosters

Coronavirus Update: MarketWatch's daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

Other COVID-19 news you should know about:

-- Thousands of nurses returned to work Thursday at Minnesota hospitals following a three-day strike over wage increases and staffing and retention made worse by the coronavirus pandemic, the Associated Press reported Members of the Minnesota Nurses' Association at 15 hospitals in the Minneapolis and Duluth areas walked off the job Monday Nurses could soon learn what impact the strike may have had on efforts to reach a new contract.

-- Munich's storied Oktoberfest is back after a two-year pandemic interruption, but visitors can expect pressure from inflation that could hardly have been imagined the last time the event was held in 2019, the AP reported separately. For one thing, the 1-liter (2-pint) mug of beer will cost between 12.60 and 13.80 euros ($12.84 and $14.07) this year, which is an increase of about 15% compared with 2019, according to the official Oktoberfest homepage. The event opens at noon Saturday when Munich's mayor taps the first keg and announces "O'zapft is," or "It's tapped" in Bavarian dialect.

-- Widespread infections and food shortages have rocked the small city of Lhasa in Tibet after more than a month of extreme COVID measures, the South China Morning Post reported. Food is running out, while people are locked in their homes or being sent to makeshift isolation centers since the first local cases were detected on Aug. 8.

-- Mainland China's southwestern municipality of Chongqing reported a case of the monkeypox virus on Friday in an individual who arrived in the country from abroad, marking the country's first known monkeypox infection, Reuters reported. The transmission risk of the case is low as the individual was put in quarantine upon arrival in Chongqing, the municipal health commission said in a statement. All close contacts had been put under medical observation in isolation.

Here's what the numbers say

The global tally of confirmed cases of COVID-19 topped 611.1 million on Friday, while the death toll rose above 6.52 million, according to data aggregated by Johns Hopkins University.

The U.S. leads the world with 95.6 million cases and 1,052,960 fatalities.

The Centers for Disease Control and Prevention's tracker shows that 224.6 million people living in the U.S. are fully vaccinated, equal to 67.7% of the total population. Just 109.2 million have had a booster, equal to 48.6% of the vaccinated population, and 22.5 million of those 50 and over who are eligible for a second booster have had one, equal to 34.7% of those who had a first booster.

-Ciara Linnane

	

(END) Dow Jones Newswires

September 16, 2022 10:22 ET (14:22 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.